Although gadolinium deposition in nephrogenic systemic fibrosis is limited to patients with abnormal renal function, more recent rat and human studies have demonstrated gadolinium deposition in specific brain structures in subjects without renal failure. We report here one of the largest studies evaluating gadolinium deposition in terms of both number of patients and number of doses, verifying the impact of the structural differences between the two most commonly used classes of agents (linear vs macrocyclic) and demonstrating a previously undescribed plateau in signal intensity ratio increase in patients who have received more than 25 administrations of gadolinium.
This abstract and the presentation materials are available to members only; a login is required.